Skip to content
  • Tuesday, 29 September 2026
  • 3:43 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries
Pharmaceutical R&D

Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries

Teuku Ryan May 2, 2026 0

Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…

Read More
Hidden Quantum Landscape Discovered in Cobalt Reveals New Potential for Future Spintronic TechnologiesStructural Defects as Charge Highways Scientists Resolve the Mystery of Lead Halide Perovskite EfficiencyThe Architecture of Intelligence Notre Dame Researchers Reveal How Whole Brain Coordination Defines the Unified MindThe Pigeon’s Inner Compass: How Liver Cells Detect Earth’s Magnetic Field
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must Have
Tolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m DealUnprecedented Genetic Study Reveals Explosive Growth Rates and Origins of Chronic Myeloid Leukemia Years Before DiagnosisAs the dream of the autonomous clinical trial dawns, agent supervision is today’s human jobNew Research Identifies Peripheral Immune Pathway as a Critical Driver of Alzheimer’s Disease Neurodegeneration
YOU MAY HAVE MISSED
Pharmaceutical R&D
Tolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m Deal
Teuku Ryan Sep 29, 2026
Stem Cell & Regenerative Medicine
Unprecedented Genetic Study Reveals Explosive Growth Rates and Origins of Chronic Myeloid Leukemia Years Before Diagnosis
Dwi Wanna Sep 29, 2026
Laboratory Automation & Robotics
As the dream of the autonomous clinical trial dawns, agent supervision is today’s human job
Lana Keisha Sep 29, 2026
Neuroscience & Brain Research
New Research Identifies Peripheral Immune Pathway as a Critical Driver of Alzheimer’s Disease Neurodegeneration
Rifan Muazin Sep 29, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ